🇺🇸 FDA
Pipeline program

TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

CL1-95035-001

Phase 2 small_molecule active

Quick answer

TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462 for MTAP-deleted advanced or metastatic solid tumors is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
MTAP-deleted advanced or metastatic solid tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials